Cargando…

Quantitative Gene Expression by Recurrence Score in ER-Positive Breast Cancer, by Age

INTRODUCTION: Breast cancer in young women (<50 years) has been associated with an increased risk of recurrence and decreased survival compared with patients older than 50. The objective of this analysis was to determine, from a large database of patients with early-stage breast cancer, if the Re...

Descripción completa

Detalles Bibliográficos
Autores principales: Swain, Sandra M., Nunes, Raquel, Yoshizawa, Carl, Rothney, Megan, Sing, Amy P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4679789/
https://www.ncbi.nlm.nih.gov/pubmed/26610382
http://dx.doi.org/10.1007/s12325-015-0268-3
_version_ 1782405583339520000
author Swain, Sandra M.
Nunes, Raquel
Yoshizawa, Carl
Rothney, Megan
Sing, Amy P.
author_facet Swain, Sandra M.
Nunes, Raquel
Yoshizawa, Carl
Rothney, Megan
Sing, Amy P.
author_sort Swain, Sandra M.
collection PubMed
description INTRODUCTION: Breast cancer in young women (<50 years) has been associated with an increased risk of recurrence and decreased survival compared with patients older than 50. The objective of this analysis was to determine, from a large database of patients with early-stage breast cancer, if the Recurrence Score(®) result (Oncotype DX(®), Genomic Health, Inc, Redwood City, CA, USA) provided clinically meaningful differences in predicted risk of recurrence in younger—compared with older—patients. METHODS: Tumor samples from patients with estrogen receptor (ER)-positive breast cancers that were successfully processed in the Genomic Health central lab between June 2004 and December 2013 for Recurrence Score and quantitative gene expression of ER, progesterone receptor (PR), and Her/2neu, were included. Descriptive statistics were used to describe the distribution of scores by age group: <40, 40–49, 50–59, 60–69, and ≥70 years, nodal status, and histologic subtype. RESULTS: Specimens from 394,031 patients [3.3% (n = 13,029) aged <40 years; 15.6% (n = 61,643) aged ≥70 years] were included; 81.6% of patients had invasive ductal carcinoma. Nodal status was specified for 362,001 patients (87.0% negative). Median Recurrence Score results were similar across risk groups. Low (<18)- and high (≥31)- risk Recurrence Score results were seen in 58.5% and 8.5% of patients, respectively. A greater proportion of patients aged <40 (14.1%) than ≥70 (8.8%) years had a high-risk score. ER expression increased as a function of age and PR single-gene and invasion gene group expression were similar across age groups. CONCLUSION: These data indicate that in patients with ER-positive breast cancer, age alone does not reflect the underlying individual tumor biology, suggesting that the Recurrence Score result may add potentially useful information for personalized treatment decisions. FUNDING: Genomic Health, Inc. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s12325-015-0268-3) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4679789
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-46797892015-12-22 Quantitative Gene Expression by Recurrence Score in ER-Positive Breast Cancer, by Age Swain, Sandra M. Nunes, Raquel Yoshizawa, Carl Rothney, Megan Sing, Amy P. Adv Ther Original Research INTRODUCTION: Breast cancer in young women (<50 years) has been associated with an increased risk of recurrence and decreased survival compared with patients older than 50. The objective of this analysis was to determine, from a large database of patients with early-stage breast cancer, if the Recurrence Score(®) result (Oncotype DX(®), Genomic Health, Inc, Redwood City, CA, USA) provided clinically meaningful differences in predicted risk of recurrence in younger—compared with older—patients. METHODS: Tumor samples from patients with estrogen receptor (ER)-positive breast cancers that were successfully processed in the Genomic Health central lab between June 2004 and December 2013 for Recurrence Score and quantitative gene expression of ER, progesterone receptor (PR), and Her/2neu, were included. Descriptive statistics were used to describe the distribution of scores by age group: <40, 40–49, 50–59, 60–69, and ≥70 years, nodal status, and histologic subtype. RESULTS: Specimens from 394,031 patients [3.3% (n = 13,029) aged <40 years; 15.6% (n = 61,643) aged ≥70 years] were included; 81.6% of patients had invasive ductal carcinoma. Nodal status was specified for 362,001 patients (87.0% negative). Median Recurrence Score results were similar across risk groups. Low (<18)- and high (≥31)- risk Recurrence Score results were seen in 58.5% and 8.5% of patients, respectively. A greater proportion of patients aged <40 (14.1%) than ≥70 (8.8%) years had a high-risk score. ER expression increased as a function of age and PR single-gene and invasion gene group expression were similar across age groups. CONCLUSION: These data indicate that in patients with ER-positive breast cancer, age alone does not reflect the underlying individual tumor biology, suggesting that the Recurrence Score result may add potentially useful information for personalized treatment decisions. FUNDING: Genomic Health, Inc. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s12325-015-0268-3) contains supplementary material, which is available to authorized users. Springer Healthcare 2015-11-26 2015 /pmc/articles/PMC4679789/ /pubmed/26610382 http://dx.doi.org/10.1007/s12325-015-0268-3 Text en © The Author(s) 2015 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Research
Swain, Sandra M.
Nunes, Raquel
Yoshizawa, Carl
Rothney, Megan
Sing, Amy P.
Quantitative Gene Expression by Recurrence Score in ER-Positive Breast Cancer, by Age
title Quantitative Gene Expression by Recurrence Score in ER-Positive Breast Cancer, by Age
title_full Quantitative Gene Expression by Recurrence Score in ER-Positive Breast Cancer, by Age
title_fullStr Quantitative Gene Expression by Recurrence Score in ER-Positive Breast Cancer, by Age
title_full_unstemmed Quantitative Gene Expression by Recurrence Score in ER-Positive Breast Cancer, by Age
title_short Quantitative Gene Expression by Recurrence Score in ER-Positive Breast Cancer, by Age
title_sort quantitative gene expression by recurrence score in er-positive breast cancer, by age
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4679789/
https://www.ncbi.nlm.nih.gov/pubmed/26610382
http://dx.doi.org/10.1007/s12325-015-0268-3
work_keys_str_mv AT swainsandram quantitativegeneexpressionbyrecurrencescoreinerpositivebreastcancerbyage
AT nunesraquel quantitativegeneexpressionbyrecurrencescoreinerpositivebreastcancerbyage
AT yoshizawacarl quantitativegeneexpressionbyrecurrencescoreinerpositivebreastcancerbyage
AT rothneymegan quantitativegeneexpressionbyrecurrencescoreinerpositivebreastcancerbyage
AT singamyp quantitativegeneexpressionbyrecurrencescoreinerpositivebreastcancerbyage